Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab Phase 2 Dose-Ranging Study in Primary Hypercholesterolemia
NCT01288443Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2011
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Jan 2011; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01288443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288443.